1. Hypersensitivity to rizatriptan or any component of the formulation
2. ischemic coronary artery disease (eg, angina pectoris, history of myocardial infarction, or documented silent ischemia)
3. significant cardiovascular disease; coronary artery vasospasm (including Prinzmetal angina); history of stroke or transient ischemic attack; peripheral vascular disease
4. ischemic bowel disease
5. uncontrolled hypertension
6. hemiplegic migraine or migraine with brainstem aura
7. during or within 2 weeks of monoamine oxidase inhibitor use; during or within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication (eg, methysergide, dihydroergotamine)

Until additional information is available, other agents are preferred for the initial treatment of migraine in pregnancy

It is not known if rizatriptan is present in breast milk.

1% to 10%:
Cardiovascular: Chest pain (≤3%), flushing (>1%), palpitations (>1%), flushing
Central nervous system: Dizziness (4% to 9%), drowsiness (4% to 8%), fatigue (adults: 4% to 7%; children: >1%), paresthesia (3% to 4%), pain (3%), feeling of heaviness (≤2%), headache (≤2%), euphoria (>1%), hypoesthesia (>1%)
Gastrointestinal: Nausea (4% to 6%), xerostomia (3%), sore throat (≤2%), abdominal distress (children: > 1%), diarrhea (> 1%), vomiting (> 1%)
Neuromuscular & skeletal: Weakness (4% to 7%), jaw pain (≤2%), jaw pressure (≤2%), jaw tightness (≤2%), neck pain (≤2%), neck pressure (≤2%), neck tightness (≤2%), tremor (> 1%)
Respiratory: Pharyngeal edema (≤2%), pressure on pharynx (≤2%), dyspnea (> 1%)

Migraine, moderate to severe, acute treatment:
5 to 10 mg as a single dose; if symptoms persist or return, may repeat dose after ≥2 hours.
The manufacturer’s labeling recommends a maximum daily dose of 30 mg per 24 hours; however, some experts recommend a maximum of 20 mg per 24 hours; efficacy data are not available for doses exceeding 20 mg in a 24-hour period

Migraine, acute treatment:
Children ≥ 6 years and Adolescents: Oral:
<40 kg: 5 mg as a single dose.
≥40 kg: 10 mg as a single dose.
Note: Safety and efficacy of multiple rizatriptan doses in a 24-hour period has not been established for pediatric patients.

There are no dosage adjustments provided in the manufacturer's labeling; however, the AUC was 44% greater in patients on hemodialysis.

There are no dosage adjustments provided in the manufacturer's labeling; however, plasma concentrations are increased by 30% in patients with moderate hepatic dysfunction.